Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia

• Main Authors: Mohammed A. Omair (Author), Tariq Alhawassi (Author), Munira Alwaihibi (Author), Ghada Aldrees (Author), Mahmoud Mosli (Author), Wesam M. Asser (Author), Maryam A. Alharaibi (Author), Atheer T. Alotaibi (Author), Doaa A. Bintaleb (Author), Najah K. Alharbi (Author), Ahmed Z. Alotaibi (Author), Wajed A. Alshammari (Author), Nouf Alanazi (Author), Ali M. Asiri (Author), Rana Almadany (Author), Hanan Al Rayes (Author), Turki Al-Thunian (Author), Moureq Alotaibi (Author), Abdulrazaq Al Jazaeri (Author)
• Format: Book
• Published: Elsevier, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The loss of patentability of many originator biologics has led to the rapid introduction of biosimilar agents. The anticipated economic benefit of introducing such agent has been accompanied by vagueness surrounding their biotechnology, approval requirements, positioning in treatment paradigms and p...